Survival after first recurrence of breast cancer: The Miami experience

Charles Vogel, S. Azevedo, S. Hilsenbeck, D. R. East, J. Ayub

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background. Four hundred thirty-three patients with recurrent breast cancer were treated by the authors at a large medical breast oncology facility from 1976-1982. The median survival time from first relapse (MSFR) for the 193 patients whose survival experience was not confounded by lead- time bias was 26 months. This MSFR is similar to that of most series published in the 1970s and 1980s and is approximately double that of series published in the 1960s. Methods. In this series, regression analysis identified disease-free interval (DFI), estrogen receptor (ER) status, and dominant disease site as significant prognostic variables, similar to other published series. Results. In 113 patients with known ER values, DFI, and dominant metastatic sites, a prognostic spectrum of MSFR patterns was identified among combinations of these three variables. The MSFR ranged from 15 months for poor risk patients with negative ER values, visceral dominant sites, and DFI of less than 24 months, to more than 90 months for good risk patients with positive ER values, soft tissue dominant sites, and DFI of more than 24 months. Although menopausal status alone was not a significant prognostic variable in regression analysis, 66% of premenopausal patients had a constellation of 'poor' prognostic variables. Conclusions. This type of prognostic factor analysis at first relapse could help identify subsets of patients who might be considered for aggressive investigational therapies such as high-dose chemotherapy with autologous bone marrow reconstitution.

Original languageEnglish
Pages (from-to)129-135
Number of pages7
JournalCancer
Volume70
Issue number1
DOIs
StatePublished - Jun 29 1992

Fingerprint

Breast Neoplasms
Recurrence
Survival
Estrogen Receptors
Regression Analysis
Investigational Therapies
Medical Oncology
Statistical Factor Analysis
Breast
Bone Marrow
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Survival after first recurrence of breast cancer : The Miami experience. / Vogel, Charles; Azevedo, S.; Hilsenbeck, S.; East, D. R.; Ayub, J.

In: Cancer, Vol. 70, No. 1, 29.06.1992, p. 129-135.

Research output: Contribution to journalArticle

Vogel, Charles ; Azevedo, S. ; Hilsenbeck, S. ; East, D. R. ; Ayub, J. / Survival after first recurrence of breast cancer : The Miami experience. In: Cancer. 1992 ; Vol. 70, No. 1. pp. 129-135.
@article{48f55e2e87a14d5aa680d46ee2035a7b,
title = "Survival after first recurrence of breast cancer: The Miami experience",
abstract = "Background. Four hundred thirty-three patients with recurrent breast cancer were treated by the authors at a large medical breast oncology facility from 1976-1982. The median survival time from first relapse (MSFR) for the 193 patients whose survival experience was not confounded by lead- time bias was 26 months. This MSFR is similar to that of most series published in the 1970s and 1980s and is approximately double that of series published in the 1960s. Methods. In this series, regression analysis identified disease-free interval (DFI), estrogen receptor (ER) status, and dominant disease site as significant prognostic variables, similar to other published series. Results. In 113 patients with known ER values, DFI, and dominant metastatic sites, a prognostic spectrum of MSFR patterns was identified among combinations of these three variables. The MSFR ranged from 15 months for poor risk patients with negative ER values, visceral dominant sites, and DFI of less than 24 months, to more than 90 months for good risk patients with positive ER values, soft tissue dominant sites, and DFI of more than 24 months. Although menopausal status alone was not a significant prognostic variable in regression analysis, 66{\%} of premenopausal patients had a constellation of 'poor' prognostic variables. Conclusions. This type of prognostic factor analysis at first relapse could help identify subsets of patients who might be considered for aggressive investigational therapies such as high-dose chemotherapy with autologous bone marrow reconstitution.",
author = "Charles Vogel and S. Azevedo and S. Hilsenbeck and East, {D. R.} and J. Ayub",
year = "1992",
month = "6",
day = "29",
doi = "10.1002/1097-0142(19920701)70:1<129::AID-CNCR2820700122>3.0.CO;2-Y",
language = "English",
volume = "70",
pages = "129--135",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Survival after first recurrence of breast cancer

T2 - The Miami experience

AU - Vogel, Charles

AU - Azevedo, S.

AU - Hilsenbeck, S.

AU - East, D. R.

AU - Ayub, J.

PY - 1992/6/29

Y1 - 1992/6/29

N2 - Background. Four hundred thirty-three patients with recurrent breast cancer were treated by the authors at a large medical breast oncology facility from 1976-1982. The median survival time from first relapse (MSFR) for the 193 patients whose survival experience was not confounded by lead- time bias was 26 months. This MSFR is similar to that of most series published in the 1970s and 1980s and is approximately double that of series published in the 1960s. Methods. In this series, regression analysis identified disease-free interval (DFI), estrogen receptor (ER) status, and dominant disease site as significant prognostic variables, similar to other published series. Results. In 113 patients with known ER values, DFI, and dominant metastatic sites, a prognostic spectrum of MSFR patterns was identified among combinations of these three variables. The MSFR ranged from 15 months for poor risk patients with negative ER values, visceral dominant sites, and DFI of less than 24 months, to more than 90 months for good risk patients with positive ER values, soft tissue dominant sites, and DFI of more than 24 months. Although menopausal status alone was not a significant prognostic variable in regression analysis, 66% of premenopausal patients had a constellation of 'poor' prognostic variables. Conclusions. This type of prognostic factor analysis at first relapse could help identify subsets of patients who might be considered for aggressive investigational therapies such as high-dose chemotherapy with autologous bone marrow reconstitution.

AB - Background. Four hundred thirty-three patients with recurrent breast cancer were treated by the authors at a large medical breast oncology facility from 1976-1982. The median survival time from first relapse (MSFR) for the 193 patients whose survival experience was not confounded by lead- time bias was 26 months. This MSFR is similar to that of most series published in the 1970s and 1980s and is approximately double that of series published in the 1960s. Methods. In this series, regression analysis identified disease-free interval (DFI), estrogen receptor (ER) status, and dominant disease site as significant prognostic variables, similar to other published series. Results. In 113 patients with known ER values, DFI, and dominant metastatic sites, a prognostic spectrum of MSFR patterns was identified among combinations of these three variables. The MSFR ranged from 15 months for poor risk patients with negative ER values, visceral dominant sites, and DFI of less than 24 months, to more than 90 months for good risk patients with positive ER values, soft tissue dominant sites, and DFI of more than 24 months. Although menopausal status alone was not a significant prognostic variable in regression analysis, 66% of premenopausal patients had a constellation of 'poor' prognostic variables. Conclusions. This type of prognostic factor analysis at first relapse could help identify subsets of patients who might be considered for aggressive investigational therapies such as high-dose chemotherapy with autologous bone marrow reconstitution.

UR - http://www.scopus.com/inward/record.url?scp=0026659404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026659404&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19920701)70:1<129::AID-CNCR2820700122>3.0.CO;2-Y

DO - 10.1002/1097-0142(19920701)70:1<129::AID-CNCR2820700122>3.0.CO;2-Y

M3 - Article

C2 - 1606535

AN - SCOPUS:0026659404

VL - 70

SP - 129

EP - 135

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -